Next Article in Journal
Targeting the Biology of Aging in Cerebrovascular Disease: Inflammation, Metabolism, Senescence, and Regeneration
Previous Article in Journal
Withaferin A Attenuates Angiotensin II-Induced Right Ventricular Dysfunction and Fibrosis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 27
Issue 4
10.3390/ijms27041879
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Role of NADPH Oxidases as Novel Therapeutic Targets for the Impaired Neurovascular Unit in the Early Stage of Diabetic Retinopathy

by
Stavroula Dionysopoulou
and
Kyriaki Thermos
*
Department of Pharmacology, School of Medicine, University of Crete, 70013 Heraklion, Greece
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2026, 27(4), 1879; https://doi.org/10.3390/ijms27041879
Submission received: 15 January 2026 / Revised: 9 February 2026 / Accepted: 13 February 2026 / Published: 15 February 2026
(This article belongs to the Special Issue Molecular Aspects of Retinal Neurodegeneration and Neuroprotection)
Browse Figures
Versions Notes

Abstract

Diabetic Retinopathy is the most common microvascular complication of diabetes. The Neurovascular Unit (NVU) is brought to the surface for its importance to retinal physiological function. Diabetes impairs the NVU through diverse causative factors, such as ischemia, oxidative stress, and excitotoxicity. The interplay between members of the above triad leads to the main pathological factors of Diabetic Retinopathy—namely, neurodegeneration, neuroinflammation, and vasculopathy. Emphasis is given to the pathology of the early stage of Diabetic Retinopathy (ESDR) and the putative new therapeutic treatments that will prevent/delay the development of the advanced stage of the disease, in which vision is compromised. NADPH oxidases (NOX1-NOX5), whose main function is to produce reactive oxygen species and induce oxidative/nitrative stress will be presented as novel therapeutic targets for the impaired Neurovascular Unit. The knowledge of the molecular mechanisms involved in the neuroprotection induced by novel specific inhibitors of NOX2 and NOX4 against the diabetic insults will confer the hope that therapeutic treatments for ESDR will evolve in the near future and be beneficial to millions of subjects who are in the early stage of Diabetic Retinopathy, as well as subjects with other complications of diabetes.

1. Introduction

Diabetes mellitus is a chronic, metabolic disorder which is rapidly affecting individuals around the world. Data from the International Diabetes Federation (IDF) indicate that in 2024, 588.7 million people globally had been diagnosed with diabetes, while this number is expected to rise to 852.5 million by 2050 [1]. The detrimental impact of chronic hyperglycemia to blood vessel physiology and integrity leads to the development of macrovascular and microvascular complications in multiple organs [2].
Diabetic Retinopathy (DR)is the most common microvascular complication of diabetes and the leading cause of preventable blindness in the working age population in developed countries [3,4,5]. It has been estimated that in 2020, 103.12 million people were living with DR, 28.54 million people suffered from vision-threatening Diabetic Retinopathy (VTDR), and 18.83 million were diagnosed with diabetic macular edema (DME). These numbers are expected to rise by 2045 to 160.50, 44.82, and 28.61 million for DR, VTDR, and DME, respectively [6].
Chronic exposure to hyperglycemia and other causal factors, such as hypertension and lipid abnormalities, is believed to initiate a cascade of biochemical and physiological alterations that ultimately lead to microvascular damage and retinal dysfunction. The clinical hallmarks of PDR include increased vascular permeability and DME due to the breakdown of the blood–retinal barrier (BRB), which causes vascular microaneurysms and endothelial cell proliferation, all of which lead to neovascularization. Due to these pathological conditions, DR was originally considered a microangiopathy, an exclusively micro vascular disease [4].
Increasing evidence has suggested that neurodegeneration is also involved in the pathophysiology of DR. Investigations in subjects [7,8] and animal models of DR [9,10,11] reported that neurodegeneration is an early event in the timeline of DR and it may also precede microvascular complications. Neurodegeneration underlies the mechanisms leading to retinal cell death, suboptimal visual acuity and blindness [4,12,13]. The hyperglycemia-induced alterations in various biochemical pathways lead to oxidative damage of micro-vessels in retina. The pathways involved are the formation of advanced glycation end products (AGE) and the activation of its receptor, RAGE, activation of hexosamine, polyol, and protein kinase C (PKC) [14].
Based on fundus detection of these microvascular lesions, DR was categorized as non-proliferativeDiabetic Retinopathy (NPDR), which is characterized by microaneurysms, hemorrhages, hard exudates [15], and PDR, in which excessive ischemia triggers an abnormal neovascularization response. The International Council of Ophthalmology also published a classification of DR, employed by clinicians, dependent on the recognition of specific anatomical disturbances. This classification further separates NPDR into mild, moderate and severe [16]. More recent clinical observations pertaining to the symptoms observed in the different stages of DR, along with preclinical studies in animal models of the disease, contributed to the development of a novel system for DR classification, placed in the early and advanced stage of Diabetic Retinopathy, ESDR and ASDR, respectively.
ASDR includes severe NPDR and PDR [13], also known as VTDR [6,17] and DME. No visible lesions were noted under the traditional fundoscopic examination of patients in the ESDR, but there was evidence consistent with early neuro-retinal deterioration [18,19] and small-scale microvascular complications [20]. Thus, ESDR includes a phase without symptoms, mild and moderate NPDR. The timely identification (screening) of preclinical DR is essential in order for the clinician to select, (a) subjects with diabetes who are at a greater risk for developing ASDR, and (b) the most effective management of the disease.
The therapeutic treatment for ESDR is presently based solely on the control of risk factors, such as blood glucose, dyslipidemia, and hypertension. Insulin, fibrates (fenofibrate), and antihypertensive treatment have a significant effect on subjects with type 2 diabetes [21]. However, some subjects with diabetes with tight glycemic and blood pressure control still develop DR [22]. The FIELD [23] and ACCORD STUDY [24] concluded that fenofibrate, a peroxisome proliferator activated–receptor alpha (PPAR) agonist, a treatment for dyslipidemia, reduced the risk of development and progression of DR in subjects with type2 diabetes. However, other investigations reported that fenofibrate mediates, via other mechanisms, anti-apoptotic activity, and improvement of endothelial function, prevention of BRB breakdown, anti-angiogenic activity, antioxidant and anti-inflammatory events [25,26,27,28].
Current pharmacological treatments focus on the ASDR [29], the stage in which vision has been compromised. Antivascular endothelial growth factor (anti-VEGF) agents, administered intravitreally, treat only the microangiopathy/vasculopathy, whereas corticosteroids reduce inflammation. However, the positive and promising results observed with the anti-VEGF treatments are hampered by their adverse side effects, such as cataract formation, retinal detachment, vitreous hemorrhage and potential loss of neural retinal cells [30]. Most importantly, they do not cause total regression of neovascularization, and do not reverse vision loss. Other commonly used treatments include laser photocoagulation, and invasive vitreo-retinal surgical procedures [31,32].
The asymptomatic nature of the initial phase of ESDR, in combination with the lack of effective treatments, may be a major cause for increasing the prevalence of ASDR. These put an enormous burden on the healthcare systems and impair the quality of life of subjects with diabetes [33]. The recognition of the pathologies of ESDR is very important for the development of new therapeutic treatments for the postponement of the ASDR and blindness.

2. Neurovascular Unit and Diabetes

Hyperglycemia induces the dysregulation of different metabolic pathways [34]. Chronic exposure to hyperglycemia, along with other factors, such as hypertension and lipid abnormalities, mentioned earlier, initiates a cascade of events that lead to the dysregulation of metabolic pathways and production of causative factors, such as ischemia, oxidative stress, and excitotoxicity [35,36]. These causative factors and the interplay between them lead to neurodegeneration, inflammation, and vasculopathy.
The American Diabetes Association (ADA) has defined DR as a highly tissue-specific neurovascular complication [37]. The term “Neurovascular Unit” (NVU) was first described in brain but was also introduced in retina. NVU describes the complex interactions, interdependency, and functional coupling of neurons, glia cells (macroglia/microglia), and the components of the vasculature (endothelial cells, pericytes) [4].
The different neural cell types [retinal ganglion cells (RGCs), bipolar, horizontal, and amacrine cells], together with glia cells [macroglia: Müller cells, astrocytes, and microglia] constitute the “neural part” of the NVU, while endothelial cells and pericytes compose the “vascular part”. Each specific cell type of NVU has a distinct role. Their coordinated function and close communication ensure the maintenance of the inner blood–retinal barrier (iBRB), as well as the regulation of blood flow locally, depending on the metabolic status of neural retina. Communication between the different cell types is achieved either directly, through physical interactions (e.g., endothelial cells and pericytes) in a paracrine and/or autocrine manner [38,39,40,41,42].
Oxidative stress (OS), excitotoxicity, imbalance in neurotrophic factors, glial dysfunction, and apoptotic cell death occur in diabetes and lead to severe dysregulation and disruption of the NVU homeostasis, causing BRB breakdown, structural and functional impairments on neurons and the vasculature [31,38,39,43]. The activation of macro- and microglia and the release of pro-inflammatory cytokines introduce a hyperglycemia-induced inflammatory component [44], which provides the link between the neural and vascular impairment of the NVU [45]. Neurodegeneration, inflammation, and vasculopathy appear to be responsible for the impairment of the NVU and BRB disruption, both critical for the pathogenesis of the ESDR. It has been reported that retinal dysfunction is present in subjects with diabetes lacking microvascular abnormalities. These latter findings led to the suggestion of renaming the microangiopathy disease, Diabetic Retinopathy (DR) to Diabetic Retinal Disease (DRD), a name in which both neurodegenerative and microvascular pathologies are involved [37,46].
New knowledge regarding the role of neurodegeneration and the impairment of NVU in the development of DR has led to a better understanding of the pathogenesis of the early stage of the disease [40]. In addition, the development of animal models of ESDR to assess the pharmacological profile of new therapeutic strategies targeting both neurodegeneration and microvascular abnormalities in diabetic animals has been established. The streptozotocin (STZ) model of DR in rodents has been employed in a large number of investigations, in which the therapeutic agents under study, namely, peptides [47,48,49], microneurotrophins [50,51], endocannabinoids [52], NADPH oxidase inhibitors [53,54] and others, are administered topically, as eye drops or intravitreally in different chronological (length of treatment) protocols. The db/db mice were also employed as a useful model for the study of neuroprotection against retinal neurodegeneration, by different pharmacological agents [55,56]. The findings of the above-mentioned investigations suggested that ESDR models and routes of administration of putative therapeutics under study protected the diabetic retina against neurodegeneration and vasculopathy. Most importantly, it has been determined that topical administration, as eyedrops, of diverse therapeutic targets, is an effective route of administration with many advantages, including the limitation of systemic side effects, the avoidance of invasive methods, and subject friendly treatment [57]. This is particularly important when using small molecules because some of them can reach the retina at pharmacological concentrations very rapidly by the trans-scleral route [58,59].
OS emerges as an important causative factor in the development of DR implicated in the impairment of NVU. NOX represent a major source of reactive oxygen species (ROS) in retina that is responsible for the development OS (Figure 1). This review focuses on the role of NADPH oxidases (NOX1, NOX2, NOX4) in the early stage of DR, their cross talk with OS and excitotoxicity, and as targets for the development of novel therapeutics for the pathologies instigated by the impairment of the NVU.

3. NADPH Oxidases (NOX): Physiology and Function

NADPH oxidases (NOX) area family of enzymes that include seven known isoforms, namely NOX1-NOX5, DUOX1/2 [60]. The main role of NOX is to produce (ROS) by catalyzing the transfer of one electron from NADPH to molecular oxygen, leading to the production of superoxide (O2−) (Figure 2). The newly formed O2−, through secondary reactions, will lead to the production of other forms of ROS, including hydrogen peroxide (H2O2) and hydroxyl radicals (OH·). Normally, the NOX-derived ROS, as well as those produced from other endogenous sources (mitochondria, xanthine oxidase, cytochrome P450 oxygenases, lipoxygenase and cyclooxygenase), are essential for a plethora of molecular and cellular processes, including host defense and the regulation of gene expression and cell signaling [61]. NOX isoforms are major sources of cytosolic ROS [62].
NOX1 isoform: It represents the first identified homolog of NOX2 [63]. The NOX1 enzymatic complex includes the trans membrane subunits NOX1 and p22phox, along with the cytosolic subunits NOX organizer 1 (NOXO1) [61]. It also requires the recruitment of Rac1 regulatory protein for the activation of the complex and the subsequent generation of superoxide [64,65].
NOX2 isoform: It was the prototypic enzyme of the NADPH oxidase family. NOX2 consists of two membrane subunits, gp91phox and p22phox, that form the NOX2 core, known as cytochrome b558, and three cytosolic subunits, p47phox, p67phox, and p40phox. Upon activation, phosphorylation of p47phox leads to the interaction with the p22phox membrane subunit and the subsequent recruitment of the cytosolic subunit sp67phox and p40phox to the NOX2 core. Rac1 or Rac2 regulatory protein binds directly to p67phox, resulting in the formation of the NOX2 activated enzymatic complex that catalyzes the production of superoxide [61,66,67].
NOX4 isoform: Unlike the other NOX isoforms, it is constitutively active. It exhibits a unique ROS generation pattern, with its rapid conversion of superoxide to hydrogen peroxide [68]. The NOX4 dependent production of ROS also requires interaction with the membrane subunit p22phox, but the function of the NOX4 isoform seems to be independent of other cytosolic regulatory proteins, including the Rac1 GTPase [69]. Interaction between p22phox and NOX4 in the endoplasmic reticulum suggested a unique mechanism of NADPH oxidase complex formation [70]. The interaction of the regulatory protein poldip2 with p22phox has been correlated with increased NOX4 enzymatic activity and its constitutive character [71], something that has to be further investigated. Most recently, NOX3 expression and function in retinal ganglion cells and amacrine cells was reported [72].

3.1. NADPH Oxidases as Critical Regulators of Oxidative Stress

OS refers to the imbalance between the excess production of ROS and their reduction from the endogenous antioxidant systems, thus leading to severe cell damage and death. Its source is from the metabolic abnormalities induced by hyperglycemia [61], but it also enhances these abnormalities causing a lethal result.
In the Central Nervous System [CNS (brain and retina)], OS leads to neurotoxicity and has been identified as one of the major mechanisms underlying the pathogenesis of vasculopathy, neurodegeneration and neuroinflammation. As mentioned above, the two major sources of ROS are NADPH oxidases (cytosolic) and mitochondria (oxidative phosphorylation, electron transport chain) [61,73].
Most cell types in CNS express multiple NOX isoforms that are differentially regulated, have distinct sub-cellular localizations and serve unique roles. Apart from their roles in the normal physiology of brain and retina, NOX isoforms are correlated with diverse CNS pathologies. In brain, NOX4, located in endothelial cells and neurons, is linked to the breakdown of the BRB and neuronal cell death that leads to ischemic stroke [74]. In retina, NOX1, NOX2, and NOX4 are expressed in RGCs, amacrine and endothelial cells, pericytes, and macro- and microglia. Their activation under pathological conditions leads to vascular dysfunction and neurodegeneration. Many investigations also reported the role of NOX in the development of inflammatory conditions [75,76,77,78].
Abnormal activity of transcription factors, such, as nuclear factor-κB (NF-κB) [79], hyperglycemia-mediated mitochondrial damage [80,81], the reduced activity of the transcription factor, nuclear factor erythroid-2-related factor 2 (Nrf2) and epigenetic regulation [82,83,84] and others [85], are correlated with ROS and DR. Even though many investigations have been performed to ascertain the exact molecular mechanisms involved in the role oxidative stress in the development of DR, further research is required to provide conclusive answers.

3.2. NADPH Oxidases and Retinal Ischemia

Ischemia is the underlying cause of many ocular diseases, including DR that leads to retinal cell loss, neovascularization, and blindness. Retinal ischemia induces the release of excess glutamate, from retinal photoreceptors, bipolar, and ganglion cells. Glutamate is the leading neurotransmitter in retina. It initiates a cascade of events that lead to excitotoxicity via the activation of different receptor subtypes belonging to ionotropic, NMDA (N-methyl-D-aspartate), AMPA (RS)-α-amino-3-hydroxy 5-methyl-4-isoxazole propionic acid hydrobromide, kainate and metabotropic receptors [86,87].Glutamate activation of NMDA receptors leads to excessive increase in calcium ions (Ca2+), activation of nitric oxide synthetase, and the release of nitric oxide (NO), thus, an increase in reactive oxygen and nitrative stress (ROS/RNS), leading to neuronal cell death. NMDA excitotoxicity has been used extensively as a model for retinal neurodegenerative disease, since NMDA receptors are located on RGCs, whose axons are responsible for forming optic nerves. NMDA excitotoxicity leads to RGC death and visual loss [88];thus, it may be considered a model of the ASDR.
Besides the Ca2+ permeable NMDA receptor, activation of other ionotropic glutamatergic receptors, as mentioned above, the non-NMDA receptors, AMPA and kainate, are also involved in retinal excitotoxicity. Their use as experimental models has played an important role in the evaluation of ischemia-related cell death and neuroprotection in retinal disease. The toxic effects of AMPA induced the attenuation of the number of viable retinal cells, activated macroglia (Müller cells) and microglia [89,90,91]. AMPA receptors are composed of tetrameric subunits, GluA1–4 that form homomeric or heteromeric complexes that are differentially expressed in retinal neurons [92]. AMPA receptors lacking the GluA2 subunit are permeable to Ca2+ and their activation leads to excitotoxicity.
AMPA excitotoxicity in experimental animals reduced retinal cell viability of cholinergic, and nitric oxide synthetase (NOS)-expressing amacrine cells, and horizontal cells, but had no effect on photoreceptors, bipolar or ganglion cells [93]. These findings led to the conclusion that AMPA excitotoxicity is an effective model for the study of the early events of retinal ischemia, and in the assessment of the neuroprotective properties of new pharmacological agents. Other studies from our lab [94,95,96] suggested that AMPA excitotoxicity not only leads to neurodegeneration, but also to neuroinflammation. The above constitute the molecular mechanisms involved in the excitotoxicity induced retinal neurodegeneration and neuroinflammation.
We also reported for the first time in the literature that AMPA increased ROS levels and OS in rodent retina. This increase was mediated by NADPH oxidases. The latter was confirmed by the use of specific inhibitors for NOX1, NOX2 and NOX4, all three displaying differential patterns, regarding their role as putative neuroprotectants and anti-inflammatory agents [97]. The findings presented in this Section 3.2 propose that there is interplay between excitotoxicity, NOX and OS in retina leading to neurodegeneration and neuroinflammation.

4. NADPH Oxidase Involvement in the Development of Diabetic Retinopathy

Studies using different in vitro and in vivo models of DR have correlated hyperglycemia with increased expression and enzymatic activity of NADPH oxidases, including NOX1/4 [75,98], NOX2 [54,99] and NOX4 [53,78] isoforms present in retinal cells. Moreover, in humans, a genome-wide association study has linked the NOX4 gene with increased risk of severe DR in subjects with diabetes type 2 diabetes, suggesting the involvement of NADPH oxidases in diabetes-induced retinal abnormalities [100]. An important mechanism that is associated with the upregulation of NOX isoforms in DR is the hyperglycemia induced activation of PKC, a significant upstream regulator of NADPH oxidases that leads to their over-activation and subsequent increase ROS production in different retinal cells [85]. In brain, glutamate excitotoxic insults also increased the expression of the NOX2 isoform in reactive microglia cells [101]. Glutamate excitotoxicity and OS are two major players in DR. The relationship between diabetes and excitotoxicity was first addressed by Ambati et al. [102]. It has been reported that the levels of glutamate and other agents, gamma-aminobutyric acid (GABA) and vascular endothelial growth factor (VEGF), are increased in the vitreous of subjects with PDR. Diabetes increases glutamate levels in humans and rodents and alters glutamate uptake, thus interfering with retinal glutamate homeostasis, leading to retinal cell death [102,103,104]. Investigations that examined the effect of diabetes on glutamate metabolism, the glutamate transporter and glutamate receptors reported that diabetes produced enzymatic abnormalities in glutamate metabolism in retina [105], as well as dysfunction of the glutamate transporter [106] and alterations of ionotropic glutamate receptors [107,108]. All these dysfunctions have been observed in ESDR.
The relationship between OS and diabetes has also been addressed. It was reported that an increase in retinal superoxide production was observed in diabetic mice (2 and 8months) via various mechanisms that included NOX signaling. Apomycin (NOX inhibitor) suppressed the diabetes-induced increase in superoxide levels, specifically in the 8-month diabetic model, and reduced capillary degeneration [109]. Many investigations aimed in deciphering the inter-relationship amongst the increase in retinal glutamate levels, oxidative stress and nitric oxide in diabetes, and the effect and therapeutic potential of antioxidants in Diabetic Retinopathy [110,111,112].
The above-mentioned findings recommend for the first time that the above triad, diabetes, excitotoxicity and oxidative stress is interrelated. OS represents a putative link between diabetes and glutamate metabolic abnormalities in retina, which are further induced by excitotoxic insults.

5. Diabetic Retinopathy: NOX2 and NOX4

Expression of NOX1, NOX2, and NOX4 isoforms has been identified in different types of retinal cells, including macro- and microglia, pericytes, and endothelial cells [75,113,114]. NOX2 activity is also increased in diabetes [115].We have reported alterations in NOX2 and NOX4 expression in retina as early as two weeks after the induction of diabetes, increasing the nitration of protein tyrosine residues, and suggesting an increase in ROS levels and OS in ESDR [53,54]. Similar results were reported by investigators using other paradigms of ESDR, with different time scales (e.g., 15 or 20day or 4-week models), and in retinas of human subjects with diabetes [116,117]. The above-mentioned results and the reports of others [118] recommend that NOX2 and NOX4 isoforms are implicated in the induction of oxidative/nitrative stress and cell damage in diabetic retina.

5.1. NOX2 Inhibitors and Mechanisms of Action in the Neuroprotection of Early Diabetic Insults

Diabetes-induced excitotoxicity affects retinal neurons, leading to neurodegeneration and retinal cell death. NOX2 was found to be involved in AMPA-induced glutamate excitotoxicity [98] and DR [54].The role played by NOX2 activation on OS was reported initially in studies examining the induction of neuronal abnormalities by NOX, due to astroglial NF-κB mediating OS [119] and neuroprotection by the deletion of NOX2 isoform [120], in a model of ischemia/reperfusion injury. An increase in glutamate levels in retinas of diabetic animals was observed as an early diabetic insult, through the impairment of the excitatory amino acid transporter 1 (EAAT1), primarily responsible for the removal of excess glutamate from the extracellular space and expressed in Müller cells [54,121,122]. NOX2 blockade with the novel NOX2 inhibitor GLX7013170 (kindly provided by Glucox AB) depicted anti-apoptotic actions, partially protected the EAAT1 and reduced glutamate levels in retinas of diabetic non-treated animals, being primarily responsible for the removal of excess glutamate from the extracellular space [54]. Changes in EAAT1 expression and function are correlated with retinal neuronal loss due to excitotoxicity. Studies in brain have also identified NOX2 as a mediator for the excessive release of glutamate and the induction of excitotoxicity in pathological conditions such as stroke [123,124].
The above-mentioned findings allude to an interplay amongst the triad, NOX2, oxidative stress, and glutamate excitotoxicity that promotes neurodegeneration and neuroinflammation in DR.

5.2. NOX4-Neuronal Cell Death and Neuroprotection

It has been reported that NOX4 is over expressed in hypoxia and in high-glucose treated primary bovine retinal capillary endothelial cells in db/db mouse retina [55]. The novel NOX4 selective inhibitor GLX7013114 was reported to improve β-islet mitochondrial activity and survival in a model of short-term stress, suggesting that it may be a putative therapeutic for type 2 diabetes [125]. It also prevented human islet cell death [126]. The results of these studies recommended that NOX4 inhibition is an important strategy to pursue for the development of new therapeutics for diabetes and DR.
GLX7013114 (kindly provided by Glucox AB), administered as eye drops, blocked the early events of DR, with respect to nitrative stress [53], in agreement with its antioxidant and neuroprotective effects in the presence of AMPA [97].
An experimental intervention with GLX701 3114, employing a preventive (2week) and therapeutic (5week) paradigm of ESDR, led to neuroprotective, anti-inflammatory, and antivascular actions [53]. GLX7013114 blocked the NOX4 induced neuronal cell death, as depicted by the depletion of NOS-expressing amacrine cells in diabetic retina, as was previously reported for other therapeutic targets in ESDR STZ-DR models [50,51,127].Key pathological features of DR pertain to the loss of amacrine cells and the marked decrease in the thickness of the nerve fiber layer (NFL) [128]. NOX4 blockade was efficacious in blocking or reversing the diabetes-induced attenuation of NFL thickness, as early as two weeks, as well as the thickness or shrinkage of the areas corresponding to ganglion cell layers (GCLs) and inner plexiform layers (IPLs) [53]. Despite the reduction in NFL thickness and intensity, no reduction was observed in the thickness neither of the GCL nor in the number of RGCs between control and diabetic animals [52].
Changes in NFL thickness represent one of the earliest structural changes at the neuronal level of the diabetic retina, thus this will play an important role on the future development of DR [129]. Progressive loss of ganglion cells was reported after axotomy of the optic nerve [130].The existence of a large number of RGCs, with no detectable retrograde Fluoro-Gold staining, a marker for neuroanatomical tracing, was reported in a mouse model of glaucoma, suggesting that part of their axons was damaged, but RGCs remained functional and expressed various RGC genes. The authors suggested that despite the degeneration of their distal part, the proximal portion of the axons remained unaffected one-month post-insult, thus contributing to RGCs’ survival [131]. In the study by Dionysopoulou et al. [53], pattern electroretinography (pERG) analysis, a sensitive measure of RGC function, was performed depicting that NOX4 blockade with GLX7013114 protected the function of RGCs against the diabetic insult. Nerve fiber layer thinning in subjects with preclinical retinopathy [132], and subjects with diabetes with or without DR [133] indicated the existence of early structural alterations in the inner retina.
All the aforementioned findings suggest that GLX7013114 support the neuroprotective effects of GLX7013114 on specific retinal neurons (NOS-expressing amacrine cells) and RGC axons against the diabetic insults of ESDR. The treatment of the diabetes-induced NFL deficits in the ESDR will be beneficial towards the viability of RGCs and the postponement of the advanced stage of the disease.

5.3. NOX4 Blockade and Vascular Leakage

VEGF is responsible for vascular permeability and neovascularization in the diabetic retina. It has been reported that OS instigates a VEGF autocrine loop in Müller cells via a mechanism involving transcription factors responsible for the transcription, translation, and release of VEGF and its receptor, VEGFR2. According to these findings it was suggested that OS triggers the VEGF autocrine loop but also sustains it [134]. Therefore, it appears that VEGF may be involved in the early and late stages of DR. There are also other mechanisms besides OS that cause upregulation of VEGF during the development of DR, including hypoxia, AGEs, and pro-inflammatory cytokines [135]. VEGF is believed to have a dual role in DR, an initial neuroprotectant of retinal neurons against the hyperglycemia-induced OS and as a subsequent facilitator or enhancer of the progression of DR [136].
Diabetes induces an increase in VEGF levels in diabetic retina. NOX4 isoform is implicated in the diabetes-induced changes in VEGF levels in rat retina. Ocular topical administration of GLX7013114 reduced VEGF levels and vascular leakage, suggesting a protective role of this NOX4 inhibitor against diabetes-induced disruption of BRB integrity [53]. These actions of GLX7013114 support its performance as a therapeutic for ESDR. Increased VEGF levels and vascular leakage were reported in other ESDR models at one week [137], two weeks [138] and six months [139].

5.4. NOX2/NOX4 and Neuroinflammation

Microglia are the resident inflammatory cells in retina. Activated microglia increase the levels of pro-inflammatory cytokines and caspase-3 expression [140,141]. Zeng et al. [142] reported that the number of diabetes-induced activated microglia was increased in different layers of the diabetic retina, as early as the first month of diabetes. A paracrine mechanism was suggested to be involved in the regulation of microglia in the inner retina.
Retinal Müller cells (macroglia) also play a role in the inflammation process induced by diabetes, and are an important source of pro-inflammatory cytokines, including, TNF-α, IL-1β, IL-6, and VEGF. These cytokines induce impairments in glutamate metabolism, directly affecting retinal neurons, vascular cells, and the integrity of the BRB. VEGF mRNA expression has been reported in retinal neurons, glia, endothelial cells, pericytes, and Retinal Pigment Epithelium (RPE) [143,144]. Many reports have suggested that neighboring cells, such as neurons and vessels, may also release VEGF and increase its levels, aiding the progression of the disease to microangiopathy.
The NOX2 isoform has been mainly associated with vascular impairments that characterize DR. Diabetes increased activation of both micro- and macroglia results in significant production and release of pro-inflammatory cytokines. Pertaining to these actions, GLX701 3170, a NOX2 inhibitor, significantly reduced the over-activation of both micro- and macroglia in the ESDR model. Based on these results, NOX2 is involved in glial associated and neurodegenerative changes present in ESDR [54]. Similarly, NOX4 blockade by GLX701 3114, decreased micro- and macroglia reactivity and the expression of pro-inflammatory cytokines suggesting a putative immunomodulatory role [53].

6. NADPH Oxidases as a Link Between ESDR Major Pathologies

All of the aforementioned preclinical data indicate that NADPH oxidases, NOX2, and NOX4 isoforms are involved in the early events of diabetes in retina. A putative mechanism of action is proposed, suggesting a dual role for NOX2 and NOX4. NOX-derived ROS act as regulators in the pathways that lead to the impairment of NVU at two levels. (1) Diabetes associated with the increase in the expression of NOX2 and NOX4 in the retina results in augmentation of ROS in the tissue. At this level, NOX-derived ROS trigger the activation of both micro- and microglia and activation of inflammatory pathways (e.g., NF-kB activation). They also initiate signaling pathways related to cell death/apoptosis, directly affecting retinal neurons and vascular cells. In addition, an up regulation in VEGF expression is also evident and contributes to vascular damage and the amplification of inflammation. (2) At the secondary level, NOX-derived ROS, produced as a result of glial activation, amplify the oxidative damage in the NVU, affecting neurons and vascular cells and initiating a loop of further induced activation of glial cells and neuroinflammation (Figure 3).
Based on this model, NADPH oxidase inhibitors can exhibit their protective actions on different levels: (a) attenuating the initial effect of oxidative stress on retinal neurons, glia and vascular cells and (b) preventing further oxidative damage in the tissue. Thus, they emerge as a promising target for further preclinical evaluation in ESDR.

7. Conclusions

The novel contribution of this review lies in the integration of emerging data suggesting a key role for NADPH oxidases as mediators of the oxidative stress effects on the diverse components of NVU in ESDR.
In this context, this review summarizes current knowledge on the diabetes-induced impairment of the NVU, through mechanisms involving ischemia, oxidative stress, and excitotoxicity. The complex interplay among this triad contributes to the three major pathologies of ESDR, namely neurodegeneration, vasculopathy, and neuroinflammation, with NADPH oxidases emerging as a putative mechanistic link across these pathologies (Figure 3).
Despite the advances in the understanding of DR development and progression, pharmaceuticals for the treatment of the pathologies of ESDR remain limited, rendering the urgent need for new treatments. NADPH oxidases have emerged as novel targets for the development of new therapeutics for the treatment of neurodegenerative disease (i.e., in brain and retina). GLX7013114 (NOX4) and GLX7013170 (NOX2) novel specific inhibitors are small molecules demonstrating broad protective effects when administered topically as eyedrops against the key pathological events of ESDR.
GLX7013114 has high affinity for NOX4, with no affinity for other NOX isoforms present in retina, and no scavenging or assay interference properties [53,60], fulfilling all the criteria that dictate the specificity of NOX inhibitors. A pharmacokinetic study substantiated that GLX7013114 reaches the retina when administered as eyedrops, justifying its efficacy and suggesting that a proper dose regimen of GLX7013114 may be beneficial for the treatment of ESDR and for delaying the development of ASDR and vision loss [53].
DR is also associated with other neurodegenerative diseases. Individuals with type 2 diabetes were reported to have a higher risk of developing neurodegenerative disease (e.g., Alzheimer’s disease) [145]. A Danish registry-based nationwide cohort study investigated whether diabetes and DR is a risk marker of AD. It was reported that individuals with DR had a 34% higher risk of incident AD, whereas individuals with diabetes without DR were less likely to develop AD compared to persons without diabetes [146].
The new knowledge evolved regarding the interplay between NOX2, oxidative stress and glutamate excitotoxicity in DR, and the molecular mechanisms responsible for the actions of NOX2 and NOX4 inhibitors in ESDR provide a better understanding for the development of new therapeutics. These will be beneficial not only for subjects with DR and other neurodegenerative diseases, but also individuals with other diabetic microvascular (diabetic cardiopathy, neuropathy, and kidney disease) and macrovascular (stroke, cardiovascular morbidity) complications, since DR is considered an independent predictor of all diabetic complications [147,148].
In closing, the findings of the preclinical investigation of NOX2 and NOX4 as therapeutics in the ESDR support their therapeutic potential. GLX7013170 and GLX7013114 inhibitors appear as lead molecules, something that must be validated clinically.

Author Contributions

S.D. wrote significant parts of this review that reflect her Master’s and Ph.D. theses, prepared Figure 1, Figure 2 and Figure 3 and revised the manuscript. K.T. wrote and revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by a grant from the Special Account for Research Funds of University of Crete [KA 10752] to K.T. Glucox Biotech, AB supported this study by generating, characterizing, and providing NOX inhibitors, and by funding a small part of the project as a donation to the Special Account for Research Funds of University of Crete [KA 10879] to K.T. It was also funded by the Christina Spyraki award to S.D. Glucox Biotech, AB had no role in the design of the study; the collection, analyses, interpretation of data; and in the writing of the manuscript.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study.

Acknowledgments

We would like to thank Dimitris Spyridakos for reading the manuscript and for his helpful comments.

Conflicts of Interest

The authors have no conflict of interest.

References

  1. International Diabetes Foundation. IDF Diabetes Atlas, 11th ed.; International Diabetes Foundation: Brussels, Belgium, 2025; Available online: http://www.diabetesatlas.org (accessed on 15 December 2025).
  2. Yamagishi, S.I.; Imaizumi, T. Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Pharm. Des. 2005, 11, 2279–2299. [Google Scholar] [CrossRef]
  3. Yau, J.W.; Rogers, S.I.; Kawasaki, R.; Lamoureux, E.L.; Kowalski, J.W.; Bek, T.; Chen, S.J.; Dekker, J.M.; Fletcher, A.; Grauslund, J.; et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012, 35, 556–564. [Google Scholar] [CrossRef]
  4. Antonetti, D.A.; Klein, R.; Gardner, T.W. Diabetic retinopathy. N. Engl. J. Med. 2012, 366, 1227–1239. [Google Scholar] [CrossRef] [PubMed]
  5. Wong, T.Y.; Cheung, C.M.G.; Larsen, M.; Sharma, S.; Simó, R. Diabetic retinopathy. Nat. Rev. Dis. Primers 2016, 2, 16012. [Google Scholar] [CrossRef] [PubMed]
  6. Teo, Z.L.; Tham, Y.C.; Yu, M.; Chee, M.L.; Rim, T.H.; Cheung, N.; Bikbov, M.M.; Wang, Y.X.; Tang, Y.; Lu, Y.; et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: Systematic review and meta analysis. Ophthalmology 2021, 128, 1580–1591. [Google Scholar] [CrossRef] [PubMed]
  7. Tavares Ferreira, J.; Alves, M.; Dias-Santos, A.; Costa, L.; Oliveira Santos, B.; Cunha, J.P.; Papoila, A.L.; Abegão Pinto, L. Retinal neurodegeneration in diabetic patients without diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2016, 57, 6455–6460. [Google Scholar] [CrossRef]
  8. Jonsson, K.B.; Frydkjaer-Olsen, U.; Grauslund, J. Vascular Changes and Neuro-degeneration in the Early Stages of Diabetic Retinopathy: Which Comes First? Ophthalmic Res. 2016, 56, 1–9. [Google Scholar] [CrossRef]
  9. Barber, A.J.; Lieth, E.; Khin, S.A.; Antonetti, D.A.; Buchanan, A.G.; Gardner, T.W. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J. Clin. Investig. 1998, 102, 783–791. [Google Scholar] [CrossRef]
  10. Barber, A.J.; Gardner, T.W.; Abcouwer, S.F. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2011, 52, 1156–1163. [Google Scholar] [CrossRef]
  11. Sohn, E.H.; van Dijk, H.W.; Jiao, C.; Kok, P.H.; Jeong, W.; Demirkaya, N.; Garmager, A.; Wit, F.; Kucukevcilioglu, M.; van Velthoven, M.E.J.; et al. Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. Proc. Natl. Acad. Sci. USA 2016, 113, 2655–2664. [Google Scholar] [CrossRef]
  12. Stitt, A.W.; Curtis, T.M.; Chen, M.; Medina, R.J.; Mckay, G.J.; Jenkins, A.; Gardiner, T.A.; Lyons, T.J.; Hammens, H.P.; Simó, R.; et al. The progress in understanding and treatment of diabetic retinopathy. Prog. Retin. Eye Res. 2016, 1, 156–186. [Google Scholar] [CrossRef]
  13. Simó, R.; Hernández, C. New insights into treating early and advanced stage diabetic retinopathy. Int. J. Mol. Sci. 2022, 23, 8513. [Google Scholar] [CrossRef] [PubMed]
  14. Ola, M.S.; Nawaz, M.I.; Siddiquei, M.M.; Al-Amro, S.; Abu El-Asrar, A.M. Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy. J. Diabetes Its Complicat. 2012, 26, 56–64. [Google Scholar] [CrossRef] [PubMed]
  15. Nayak, J.; Bhat, P.S.; Acharya, R.P.; Lim, C.M.; Kagathi, M. Automated identification of diabetic retinopathy stages using digital fundus images. J. Med. Syst. 2008, 2, 107–115. [Google Scholar] [CrossRef] [PubMed]
  16. Yang, Z.; Tan, T.-E.; Shao, Y.; Wong, T.Y.; Li, X.R. Classification of diabetic retinopathy: Past, present and future. Front. Endocrinol. 2022, 13, 1079217. [Google Scholar] [CrossRef]
  17. Zhang, X.; Saaddine, J.B.; Chou, C.-F.; Cotch, M.F.; Cheng, Y.J.; Geiss, L.S.; Gregg, E.W.; Albright, A.L.; Klein, B.E.K.; Klein, R. Prevalence of Diabetic Retinopathy in the United States, 2005–2008. JAMA 2010, 304, 649–656. [Google Scholar] [CrossRef]
  18. Toprak, I.; Fenkci, S.M.; Fidan Yaylali, G.; Martin, C.; Yaylali, V. Early retinal neurodegeneration in preclinical diabetic retinopathy: A multifactorial investigation. Eye 2020, 34, 1100–1107. [Google Scholar] [CrossRef]
  19. Park, J.C.; Chen, Y.F.; Liu, M.; Liu, K.; McAnany, J.J. Structural and functional abnormalities in early-stage diabetic retinopathy. Curr. Eye Res. 2020, 45, 975–985. [Google Scholar] [CrossRef]
  20. Cao, D.; Yang, D.; Huang, Z.; Zeng, Y.; Wang, J.; Hu, Y.; Zhang, L. Optical coherence tomography angiography discerns preclinical diabetic retinopathy in eyes of patients with type 2 diabetes without clinical diabetic retinopathy. Acta Diabetol. 2018, 55, 469–477. [Google Scholar] [CrossRef]
  21. Dissanayake, H.A.; Kiire, C.A.; Preiss, D.; Tan, G.D.J. The use of fenofibrate in diabetic retinopathy: Narrative review. J. Diabetes Its Complicat. 2025, 39, 109135. [Google Scholar] [CrossRef]
  22. Zhang, L.; Krzentowski, G.; Albert, A.; Lefebvre, P.J. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 2001, 24, 1275–1279. [Google Scholar] [CrossRef] [PubMed]
  23. Keech, A.C.; Mitschell, P.; Summanen, P.A.; O’Day, J.; Davis, T.M.E.; Moffitt, M.S.; Taskinen, M.R.; Simes, R.J.; Tse, D.; Williamson, E. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial study): A randomised controlled trial. Lancet 2007, 370, 1687–1697. [Google Scholar] [CrossRef] [PubMed]
  24. The ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N. Engl. J. Med. 2010, 363, 233–244. [Google Scholar] [CrossRef] [PubMed]
  25. Wong, T.Y.; Simó, R.; Mitchell, P. Fenofibrate—A Potential Systemic Treatment for Diabetic Retinopathy? Am. J. Ophthalmol. 2012, 154, 6–12. [Google Scholar] [CrossRef]
  26. Kim, J.; Ahn, J.H.; Kim, J.H.; Yu, Y.S.; Kim, H.S.; Ja, J.; Shinn, S.H.; Oh, Y.S. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp. Eye Res. 2007, 84, 886–893. [Google Scholar] [CrossRef]
  27. Simó, R.; Roy, S.; Behar-Cohen, F.; Keech, A.; Mitchell, P.; Wong, T.Y. Fenofibrate: A new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. Curr. Med. Chem. 2013, 20, 3258–3266. [Google Scholar] [CrossRef]
  28. Roy, S.; Kim, D.; Hernández, C.; Simó, R.; Roy, S. Beneficial effects of fenofibric acid on over expression of extracellular matrix components, COX-2, and impairment of endothelial permeability associated with diabetic retinopathy. Exp. Eye Res. 2015, 140, 124–129. [Google Scholar] [CrossRef]
  29. Mounirou, B.A.; Adam, N.D.; Yakoura, A.K.; Aminou, M.S.; Liu, Y.T.; Tan, L.Y. Diabetic retinopathy: An overview of treatments. Indian J. Endocrinol. Metabol. 2022, 26, 111–118. [Google Scholar] [CrossRef]
  30. Simó, R.; Hernández, C. Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Prog. Retin. Eye Res. 2015, 48, 160–180. [Google Scholar] [CrossRef]
  31. Duh, E.J.; Sun, J.K.; Stitt, A.W. Diabetic Retinopathy: Current Understanding, Mechanisms, and Treatment Strategies. JCI Insight 2017, 2, e93751. [Google Scholar] [CrossRef]
  32. Tomita, Y.; Lee, D.; Tsubota, K.; Negishi, K.; Kurihara, T. Updates on the Current Treatments for Diabetic Retinopathy and Possibility of Future Oral Therapy. J. Clin. Med. 2021, 10, 4666. [Google Scholar] [CrossRef]
  33. Lundeen, E.A.; Kim, M.; Rein, D.B.; Wittenborn, J.S.; Saaddine, J.; Ehrlich, J.R.; Holliday, C.S. Trends in the prevalence and treatment of diabetic macular edema and vision-threatening diabetic retinopathy among commercially insured adults aged <65 years. Diabetes Care 2023, 46, 687–696. [Google Scholar] [CrossRef] [PubMed]
  34. Lechner, J.; O’Leary, O.E.; Stitt, A.W. The pathology associated with diabetic retinopathy. Vis. Res. 2017, 139, 7–14. [Google Scholar] [CrossRef] [PubMed]
  35. Pulido, J.E.; Pulido, J.S.; Erie, J.C.; Arroyo, J.; Bertram, K.; Lu, M.-J.; Shippy, S.S. A role for excitatory amino acids in diabetic eye disease. Exp. Diabetes Res. 2007, 2007, 36150. [Google Scholar] [CrossRef] [PubMed]
  36. Hammes, H.P. Diabetic retinopathy: Hyperglycemia, oxidate stress and beyond. Diabetologia 2018, 61, 29–38. [Google Scholar] [CrossRef]
  37. Solomon, S.D.; Chew, E.; Duh, E.J.; Sobrin, L.; Sun, J.K.; VanderBeek, B.L.; Wykoff, C.; Gardner, T.W. Diabetic Retinopahy: A position statement by the American Diabetes Association. Diabetes Care 2017, 40, 412–418, Erratum in Diabetes Care 2017, 40, 1285. [Google Scholar] [CrossRef]
  38. Gardner, T.W.; Davila, J.R. The neurovascular unit and the pathophysiologic basis of diabetic retinopathy. Graefe’s Arch. Clin. Exp. Ophthalmol. 2017, 255, 1–6. [Google Scholar] [CrossRef]
  39. Zafar, S.; Sachdeva, M.; Frankfort, B.J.; Channa, R. Retinal Neurodegeneration as an Early Manifestation of Diabetic Eye Disease and Potential Neuroprotective Therapies. Curr. Diabet. Rep. 2019, 19, 2–13. [Google Scholar] [CrossRef]
  40. Simo, R.; Simo-Servat, O.; Bogdanov, P.; Hernandez, C. Neurovascular Unit: A New Target for Treating Early Stages of Diabetic Retinopathy. Pharmaceutics 2021, 13, 1320. [Google Scholar] [CrossRef]
  41. Yang, I.; Zexin, X.; Xu, H.M.; Chen, Y.; Cao, M.; Yi, M.; Fu, M. Autophagy in the Retinal Neurovascular Unit: New Perspectives into Diabetic Retinopathy. J. Diabetes 2023, 15, 382–396. [Google Scholar] [CrossRef]
  42. Hawkins, B.T.; Davis, T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 2005, 57, 173–185. [Google Scholar] [CrossRef] [PubMed]
  43. Augustine, J.; Evan, P.; Troendle, E.P.; Barabas, P.; McAlese, C.A.; Friedel, T.; Stitt, A.; Curtis, T.M. The Role of Lipoxidation in the Pathogenesis of Diabetic Retinopathy. Front. Endocrinol. 2021, 11, 621938. [Google Scholar] [CrossRef] [PubMed]
  44. Tang, J.; Kern, T.S. Inflammation in diabetic retinopathy. Prog. Retin. Eye Res. 2011, 30, 343–358. [Google Scholar] [CrossRef] [PubMed]
  45. Ramos, H.; Hernández, C.; Simó, R.; Simó-Servat, O. Inflammation: The Link between Neural and Vascular Impairment in the Diabetic Retina and Therapeutic Implications. Int. J. Mol. Sci. 2023, 24, 8796. [Google Scholar] [CrossRef]
  46. Simó, R.; Hernández, C. Topical ocular administration of DPP-IV inhibitors: A new approach for treating diabetes induced retinal neurodegeneration. NeuralRegen. Res. 2024, 19, 713–714. [Google Scholar] [CrossRef]
  47. Hernández, C.; García-Ramírez, M.; Corraliza, L.; Fernández-Carneado, J.; Farrera-Sinfreu, J.; Ponsati, B.; González-Rodríguez, A.; Valverde, A.M.; Simó, R. Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes. Diabetes 2013, 62, 2569–2578. [Google Scholar] [CrossRef]
  48. Bogdanov, P.; Simó-Servat, O.; Sampedro, J.; Solà-Adell, C.; Garcia-Ramírez, M.; Ramos, H.; Guerrero, M.; Suñé-Negre, J.M.; Ticó, J.R.; Montoro, B.; et al. Topical administration of bosentan prevents retinal neurodegeneration in experimental diabetes. Int. J. Mol. Sci. 2018, 19, 3578. [Google Scholar] [CrossRef]
  49. Hernández, C.; Bogdanov, P.; Corraliza, L.; García-Ramírez, M.; Solà-Adell, C.; Arranz, J.A.; Arroba, A.I.; Valverde, A.M.; Simó, R. Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes 2016, 65, 172–187. [Google Scholar] [CrossRef]
  50. Ibán-Arias, R.; Lisa, S.; Mastrodimou, N.; Kokona, D.; Koulakis, E.; Iordanidou, P.; Kouvarakis, A.; Fothiadaki, M.; Papadogkonaki, S.; Sotiriou, A.; et al. The Synthetic MicroneurotrophinBNN27 affects retinal function in rats with streptozotocin-induced diabetes. Diabetes 2018, 67, 321–333. [Google Scholar] [CrossRef]
  51. Ibán-Arias, R.; Lisa, S.; Poulaki, S.; Mastrodimou, N.; Charalampopoulos, I.; Gravanis, A.; Thermos, K. Effect of topical administration of the microneurotrophin BNN27 in the diabetic rat retina. Graefe’s Arch. Clin. Exp. Ophthalmol. 2019, 257, 429–2436. [Google Scholar] [CrossRef]
  52. Spyridakos, D.; Mastrodimou, N.; Vemuri, K.; Ho, T.C.; Nikas, S.P.; Makriyannis, A.; Thermos, K. Blockade of CB1 or Activation of CB2 Cannabinoid Receptors Is Differentially Efficacious in the Treatment of the Early Pathological Events in Streptozotocin-Induced Diabetic Rats. Int. J. Mol. Sci. 2023, 24, 240. [Google Scholar] [CrossRef]
  53. Dionysopoulou, S.; Wikstrom, P.; Bucolo, C.; Romano, G.L.; Micale, V.; Svensson, R.; Spyridakos, D.; Mastrodimou, N.; Georgakis, S.; Verginis, P.; et al. Topically Administered NOX4 Inhibitor, GLX701 3114, Is Efficacious in Treating the Early Pathological Events of Diabetic Retinopathy. Diabetes 2023, 72, 638–652. [Google Scholar] [CrossRef] [PubMed]
  54. Dionysopoulou, S.; Wikstrom, P.; Walum, E.; Georgakis, S.; Thermos, K. Investigation of the Effects of a Novel NOX2 Inhibitor, GLX701 3170, against Glutamate Excitotoxicity and Diabetes Insults in the Retina. Pharmaceuticals 2024, 17, 393. [Google Scholar] [CrossRef] [PubMed]
  55. Li, J.; Wang, J.J.; Yu, Q.; Chen, K.; Mahadev, K.; Zhang, S.X. Inhibition of reactive oxygen species by lovastatin downregulates vascular endothelial growth factor expression and ameliorates blood-retinal barrier breakdown in db/db mice: Role of NADPH oxidase 4. Diabetes 2010, 59, 1528–1538. [Google Scholar] [CrossRef] [PubMed]
  56. Bogdanov, P.; Corraliza, L.; Villena, J.A.; Carvalho, A.R.; Garcia-Arumí, J.; Ramos, D.; Ruberte, J.; Simó, R.; Hernández, C. The db/db mouse: A useful model for the study of diabetic retinal neurodegeneration. PLoS ONE 2014, 9, e97302, Correction in PLoS ONE 2014, 9, e106227. [Google Scholar] [CrossRef]
  57. Thagaard, M.S.; Vergmann, A.S.; Grauslund, J. Topical Treatment of Diabetic Retinopathy: A Systematic Review. Acta Ophthalmol. 2022, 100, 136–147. [Google Scholar] [CrossRef]
  58. Hernández, C.; Bogdanov, P.; Solà-Adell, C.; Sampedro, J.; Valeri, M.; Genís, X.; Simó-Servat, O.; García-Ramírez, M.; Simó, R. Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes. Diabetologia 2017, 60, 2285–2298. [Google Scholar] [CrossRef]
  59. Hernández, C.; Ramos, H.; Létondor, A.; Simó, R. Ocular and Plasma Pharmacokinetics of Sitagliptin Eye Drops: Preclinical Data. Pharmaceuticals 2024, 17, 1579. [Google Scholar] [CrossRef]
  60. Augsburger, F.; Filippova, A.; Rasti, D.; Seredenia, T.; Lam, M.; Maghzal, G.; Mahiout, Z.; Jansen-Dürr, P.; Knaus, U.G.; Doroshow, J. Pharmacological characterization of the seven human NOX isoforms and their inhibitors. Redox Biol. 2019, 26, 101272. [Google Scholar] [CrossRef]
  61. Bedard, K.; Krause, K.-H. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol. Rev. 2007, 87, 245–313. [Google Scholar] [CrossRef]
  62. Frey, R.S.; Ushio-Fukai, M.; Malik, A.B. NADPH oxidase-dependent signaling in endothelial cells: Role in physiology and pathophysiology. Antioxid. Redox Signal. 2009, 11, 791–810. [Google Scholar] [CrossRef] [PubMed]
  63. Suh, Y.-A.; Arnold, R.S.; Lassegue, B.; Shi, J.; Xu, X.; Sorescu, D.; Chung, A.B.; Griendling, K.K.; Lambeth, J.D. Cell Transformation by the Superoxide-Generating Oxidase Nox1. Nature 1999, 401, 79–82. [Google Scholar] [CrossRef] [PubMed]
  64. Cheng, G.; Diebold, B.A.; Hughes, Y.; Lambeth, J.D. Nox1-Dependent Reactive Oxygen Generation Is Regulated by Rac1. J. Biol. Chem. 2006, 281, 17718–17726. [Google Scholar] [CrossRef] [PubMed]
  65. Ueyama, T.; Miklós, G.; Leto, T.L. Involvement of Rac1 in Activation of Multicomponent Nox1 and Nox 3 Based NADPH Oxidases. Mol. Cell. Biol. 2006, 26, 2160–2174. [Google Scholar] [CrossRef]
  66. Noreng, S.; Ota, N.; Sun, Y.; Ho, H.; Johnson, M.; Arthur, C.P.; Schneider, K.; Lehoux, I.; Davies, C.W.; Mortara, K.; et al. Structure of the core human NADPH oxidase NOX2. Nat. Commun. 2022, 13, 6079. [Google Scholar] [CrossRef]
  67. Chan, E.C.; van Wijngaarden, P.; Liu, G.S.; Jiang, F.; Peshavariya, H.; Dusting, G.J. Involvement of Nox2 NADPH Oxidase in Retinal Neovascularization. Investig. Opthalmol. Vis. Sci. 2013, 54, 7061–7067. [Google Scholar] [CrossRef]
  68. Serrander, L.; Cartier, L.; Bedard, K.; Banfi, B.; Lardy, B.; Plastre, O.; Sienkiewicz, A.; Fórró, L.; Schlegel, W.; Krause, K.H. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem. J. 2007, 406, 105–111. [Google Scholar] [CrossRef]
  69. Martyn, P.M.; Frederick, L.M.; von Loehneysen, K.; Dinauer, M.C.; Kraus, U.G. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell. Signal. 2006, 18, 69–82. [Google Scholar] [CrossRef]
  70. Zana, M.; Péterfi, Z.; Kovács, H.A.; Tóth, Z.E.; Enyedi, B.; Morel, F.; Paclet, M.-H.; Donkó, Á.; Morand, S.; Leto, T.L.; et al. Interaction between p22phox and Nox4 in the endoplasmic reticulum suggests a unique mechanism of NADPH oxidase complex formation. Free Radic. Biol. Med. 2018, 116, 41–49. [Google Scholar] [CrossRef]
  71. Lyle, A.L.; Deshpande, N.N.; Taniyama, Y.; Seidel-Rogol, B.; Pounkova, L.; Du, P.; Papaharalambus, C.; Lassègue, B.; Griendling, K.K. Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells. Circ. Res. 2009, 105, 249–259. [Google Scholar] [CrossRef]
  72. Ueyama, T.; Yamaguchi, K.; Aoyama, Y.; Aoshima, K.; Onizuka, M.; Tamagawa, T.; Kitayama, S.; Ueyama, J.; Okamoto, K.; Mohri, H.; et al. Nox3 expression and function in retinal ganglion cells and Amacrine cells. Cell. Mol. Life Sci. 2026, 83, 28. [Google Scholar] [CrossRef] [PubMed]
  73. Altenhöfer, S.; Kleikers, P.W.M.; Radermacher, K.A.; Scheurer, P.; Hermans, J.J.R.; Schiffers, P.; Ho, H.; Wingler, K.; Schmid, H.H.H.W. The NOX toolbox: Validating the role of NADPH oxidases in physiology and disease. Cell. Mol. Life Sci. 2012, 69, 2327–2343. [Google Scholar] [CrossRef] [PubMed]
  74. Casas, A.I.; Geuss, E.; Kleikers, P.W.M.; Stine, M.; Herrmann, A.M.; Buendia, I.; Egea, J.; Sven, G.; Meuth, M.; Lopez, G.; et al. NOX4-dependent neuronal autotoxicity and BBB breakdown explain the superior sensitivity of the brain to ischemic damage. Proc. Nat. Acad. Sci. USA 2017, 114, 12315–12320. [Google Scholar] [CrossRef] [PubMed]
  75. Wilkinson-Berka, J.L.; Deliyanti, D.; Rana, I.; Miller, A.G.; Agrotis, A.; Armani, R.; Szyndralewiez, C.; Wingler, K.; Touyz, R.M.; Cooper, M.E.; et al. NADPH Oxidase, NOX1, Mediates Vascular Injury in Ischemic Retinopathy. Antioxid. Redox Signal. 2014, 20, 2726–2740. [Google Scholar] [CrossRef]
  76. Al-Shabrawey, M.; Rojas, M.; Sanders, T.; Behzadian, A.; El-Remessy, A.; Bartoli, M.; Parpia, A.K.; Liou, G.; Caldwell, R.B. Role of NADPH oxidase in retinal vascular inflammation. Investig. Ophthalmol. Vis. Sci. 2008, 49, 3239–3244. [Google Scholar] [CrossRef]
  77. Deliyanti, D.; Wilkinson-Berka, J.L. Inhibition of NOX1/4 with GKT137831: A potential novel treatment to attenuate neuroglial cell inflammation in the retina. J. Neuroinflamm. 2015, 12, 136. [Google Scholar] [CrossRef]
  78. Ahmad, A.; Nawaz, M.I.; Siddiquei, M.M.; El-Asrar, A.M. Apocynin ameliorates NADPH oxidase 4 (NOX4) induced oxidative damage in the hypoxic human retinal Müller cells and diabetic rat retina. Mol. Cell. Biochem. 2021, 476, 2099–2109. [Google Scholar] [CrossRef]
  79. Romeo, G.; Liu, W.H.; Asnaghi, V.; Kern, T.S.; Lorenzi, M. Activation of nuclear factor-κB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 2002, 51, 2241–2248. [Google Scholar] [CrossRef]
  80. Kowluru, R.A.; Mishra, M. Oxidative stress, mitochondrial damage and diabetic retinopathy. Biochim. Biophys. Acta 2015, 1852, 2474–2483. [Google Scholar] [CrossRef]
  81. Kowluru, R.A.; Kowluru, A.; Mishra, M.; Kumara, B. Oxidative stress and epigenetic modifications in the pathogenesis of diabetic retinopathy. Prog. Retin. Eye Res. 2015, 48, 40–61. [Google Scholar] [CrossRef]
  82. Zhong, Q.; Mishra, M.; Kowluru, R.A. Transcription factor Nrf2-mediated antioxidant defense system in the development of diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2013, 54, 3941–3948. [Google Scholar] [CrossRef] [PubMed]
  83. Kowluru, R.A.; Mishra, M. Epigenetic regulation of redox signaling in diabetic retinopathy: Role of Nrf2. Free Radic. Biol. Med. 2017, 103, 155–164. [Google Scholar] [CrossRef] [PubMed]
  84. Kowluru, R.A. Cross Talks between Oxidative Stress, Inflammation and Epigenetics in Diabetic Retinopathy. Cells 2023, 12, 300. [Google Scholar] [CrossRef] [PubMed]
  85. Kang, Q.; Yang, C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020, 37, 101799. [Google Scholar] [CrossRef]
  86. Olney, J.W. Glutamate-induced retinal degeneration in neonatal mice. Electron microscopy of the acutely evolving lesion. J. Neuropathol. Exp. Neurol. 1969, 28, 455–474. [Google Scholar] [CrossRef]
  87. Osborne, N.N.; Casson, R.J.; Wood, J.P.M.; Chidlow, G.; Graham, M.; Melena, J. Retinal ischemia: Mechanisms of damage and potential therapeutic strategies. Prog. Retin. Eye Res. 2004, 23, 91–147. [Google Scholar] [CrossRef]
  88. Izumi, Y.; Hammerman, S.B.; Kirby, C.O.; Benz, A.M.; Olney, J.W.; Zorumski, C.F. Involvement of glutamate in ischemic neurodegeneration in isolated retina. Vis. Neurosci. 2003, 20, 97–107. [Google Scholar] [CrossRef]
  89. Andrés, N.; Malpesa, Y.; Rodríguez, M.J.; Mahy, N. Low sensitivity of retina to AMPA-induced calcification. J. Neurosci. Res. 2003, 72, 543–548. [Google Scholar] [CrossRef]
  90. Liu, S.J.; Zukin, R.S. Ca2+-permeable AMPA receptors in synaptic plasticity and neuronal death. Trends Neurosci. 2007, 30, 126–134. [Google Scholar] [CrossRef]
  91. Lu, Y.M.; Yin, H.Z.; Chiang, J.; Weiss, J.H. Ca2+ permeable AMPA/kainate and NMDA channels: High rate of Ca2+ influx underlies potent induction of injury. J. Neurosci. 1996, 16, 5457–5465. [Google Scholar] [CrossRef]
  92. Choi, D.W.; Rothman, S.M. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Ann. Rev. Neurosci. 1990, 13, 171–182. [Google Scholar] [CrossRef] [PubMed]
  93. Kiagiadaki, F.; Thermos, K. Effect of intravitreal administration of somatostatin and sst2 analogs on AMPA-induced neurotoxicity in rat retina. Investig. Ophthalmol. Vis. Sci. 2008, 49, 3080–3089. [Google Scholar] [CrossRef] [PubMed][Green Version]
  94. Kokona, D.; Charalampopoulos, I.; Pediaditakis, I.; Gravanis, A.; Thermos, K. The neurosteroid dehydroepiandrosterone (DHEA) protects the retina from AMPA-induced excitotoxicity: NGF TrkA receptor involvement. Neuropharmacology 2012, 62, 2106–2117. [Google Scholar] [CrossRef] [PubMed]
  95. Kokona, D.; Thermos, K. Synthetic and endogenous cannabinoids protect retinal neurons from AMPA excitotoxicity in vivo, via activation of CB1 receptors: Involvement of PI3K/Akt and MEK/ERK signaling pathways. Exp. Eye Res. 2015, 136, 45–58. [Google Scholar] [CrossRef]
  96. Kokona, D.; Spyridakos, D.; Tzatzarakis, M.; Papadogkonaki, S.; Filidou, E.; Arvanitidis, K.I.; Kolios, G.; Lamani, M.; Makriyannis, A.; Malamas, M.; et al. The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity. Neuropharmacology 2021, 185, 108450. [Google Scholar] [CrossRef]
  97. Dionysopoulou, S.; Wikström, P.; Walum, E.; Thermos, K. Effect of NADPH oxidase inhibitors in an experimental retinal model of excitotoxicity. Exp. Eye Res. 2020, 2020, 108232. [Google Scholar] [CrossRef]
  98. Deliyanti, D.; Alrashdi, S.F.; Touyz, R.M.; Kennedy, C.R.; Jha, J.C.; Cooper, M.E.; Jandeleit-Dahm, K.A.; Wilkinson-Berka, J.L. Nox (NADPH oxidase) 1, Nox4, and Nox5 promote vascular permeability and neovascularization in retinopathy. Hypertension 2020, 75, 1091–1101. [Google Scholar] [CrossRef]
  99. Kowluru, R.A.; Mishra, M.; Kumar, B. Diabetic Retinopathy and Transcriptional Regulation of a Small Molecular Weight G Protein, Rac1. Exp. Eye Res. 2016, 147, 72–77. [Google Scholar] [CrossRef]
  100. Meng, W.; Shah, K.P.; Pollack, S.; Toppila, I.; Hebert, H.L.; McCarthy, M.I.; Groop, L.; Ahlqvist, E.; Lyssenko, V.; Agardh, E.; et al. A genome-wide association study suggests new evidence for an association of the NADPH oxidase 4 (NOX4) gene with severe diabetic retinopathy in type 2 diabetes. Acta Ophthalmol. 2018, 96, e811–e819. [Google Scholar] [CrossRef]
  101. Guemez-Gamboa, A.; Estrada-Sanchez, A.M.; Montiel, T.; Paramo, B.; Massieu, L.; Moran, J. Activation of NOX2 by the stimulation of ionotropic and metabotropic glutamate receptors contributes to glutamate neurotoxicity in vivo through the production of reactive oxygen species and calpain activation. J. Neuropathol. Exp. Neurol. 2011, 70, 1020–1035. [Google Scholar] [CrossRef]
  102. Ambati, J.; Chawla, D.K.; D’Angio, C.T.; Guillet, E.G.; Rose, S.J.; Vanderlinde, R.E.; Ambati, B.K. Elevated γ-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch. Ophthalmol. 1997, 115, 1161–1166. [Google Scholar] [CrossRef]
  103. Lieth, E.; Barber, A.J.; Xu, B.; Dice, C.; Ratz, M.J.; Tanase, D.; Strother, J.M. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Diabetes 1998, 47, 815–820. [Google Scholar] [CrossRef] [PubMed]
  104. Kowluru, R.A.; Engerman, R.L.; Case, G.L.; Kerns, T.S. Retinal glutamate in diabetes and effect of antioxidants. Neurochem. Int. 2001, 38, 385–390. [Google Scholar] [CrossRef] [PubMed]
  105. Lieth, E.; LaNoue, K.F.; Antonetti, D.A.; Ratz, M. Diabetes reduces glutamate oxidation and glutamine synthesis in the retina. Exp. Eye Res. 2000, 70, 723–730. [Google Scholar] [CrossRef] [PubMed]
  106. Li, Q.; Puro, D.G. Diabetes-induced dysfunction of the glutamate transporter in retinal Müller cells. Investig. Ophthalmol. Vis. Sci. 2002, 43, 3109–3116. [Google Scholar]
  107. Santiago, A.R.; Gaspar, J.M.; Baptista, F.I.; Cristóvão, A.J.; Santos, P.F.; Kamphuis, W.; Ambrósio, A.F. Diabetes changes the levels of ionotropic glutamate receptors in the rat retina. Mol. Vis. 2009, 15, 1620–1630. [Google Scholar]
  108. Santiago, A.R.; Rosa, S.C.; Santos, P.F.; Cristóvão, A.J.; Barber, A.J.; Ambrosio, A.F. Elevated glucose changes the expression of ionotropic glutamate receptor subunits and impairs calcium homeostasis in retinal neural cells. Investig. Ophthalmol. Vis. Sci. 2006, 47, 4130–4137. [Google Scholar] [CrossRef]
  109. Du, Y.; Cramer, M.; Lee, C.A.; Tang, J.; Muthusamy, A.; Antonetti, D.A.; Jin, H.; Palczewski, K.; Kern, T.S. Adrenergic and Serotonin Receptors Affect Retinal Superoxide Generation in Diabetic Mice: Relationship to Capillary Degeneration and Permeability. FASEB J. 2015, 29, 2194–2204. [Google Scholar] [CrossRef]
  110. Carmo, A.; Lopes, C.; Santos, M.; Proença, R.; Cunha-Vaz, J.; Carvalho, A.P. Nitric oxide synthase activity and L-arginine metabolism in the retinas from streptozotocin-induced diabetic rats. Gen. Pharmacol. 1998, 30, 319–324. [Google Scholar] [CrossRef]
  111. Trotti, D.; Danbolt, N.C.; Volterra, A. Glutamate transporters are oxidant-vulnerable: A molecular link between oxidative and excitotoxic neurodegeneration? Trends Pharmacol. Sci. 1998, 9, 328–334. [Google Scholar] [CrossRef]
  112. Kowluru, R.A.; Kennedy, A. Therapeutic potential of anti-oxidants and diabetic retinopathy. Expert Opin. Investig. Drugs 2001, 10, 1665–1676. [Google Scholar] [CrossRef] [PubMed]
  113. Appukuttan, B.; Ma, Y.; Stempel, A.; Ashander, L.M.; Deliyanti, D.; Wilkinson-Berka, J.L.; Smith, J.R. Effect of NADPH oxidase 1 and 4 blockade in activated human retinal endothelial cells. Clin. Exp. Ophthalmol. 2018, 46, 652–660. [Google Scholar] [CrossRef] [PubMed]
  114. Dvoriantchikova, G.; Grant, J.; Santos, A.R.C.; Hernandez, E.; Ivanov, D. Neuronal NAD(P)H Oxidases Contribute to ROS Production and Mediate RGC Death after Ischemia. Investig. Ophthalmol. Vis. Sci. 2012, 53, 2823–2830. [Google Scholar] [CrossRef] [PubMed]
  115. Kowluru, A.; Kowluru, R.A. Phagocyte-like NADPH oxidase [Nox2] in cellular dysfunction in models of glucolipotoxicity and diabetes. Biochem. Pharmacol. 2014, 88, 275–283. [Google Scholar] [CrossRef]
  116. El-Remessy, A.B.; Behzadian, M.A.; Abou-Mohamed, G.; Franklin, T.; Caldwell, R.W.; Caldwell, R.B. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am. J. Pathol. 2003, 162, 1995–2004. [Google Scholar] [CrossRef]
  117. Ali, T.K.; Matragoon, S.; Pillai, B.A.; Liou, G.I.; El-Remessy, A.B. Peroxynitrite mediates retinal neurodegeneration by inhibiting nerve growth factor survival signaling in experimental and human diabetes. Diabetes 2008, 57, 889–898. [Google Scholar] [CrossRef]
  118. Hernández-Ramírez, E.; Sánchez-Chávez, G.; Estrella-Salazar, L.A.; Salceda, R. Nitrosative Stress in the Rat Retina at the Onset of Streptozotocin-Induced Diabetes. Cell. Physiol. Biochem. 2017, 42, 2353–2363. [Google Scholar] [CrossRef]
  119. Barakat, D.J.; Dvoriantchikova, G.; Ivanov, D.; Shestopalov, V.I. Astroglial NF-κB mediates oxidative stress by regulation of NADPH oxidase in a model of retinal ischemia reperfusion injury. J. Neurochem. 2012, 120, 586–597. [Google Scholar] [CrossRef]
  120. Yokota, H.; Narayanan, S.P.; Zhang, W.; Liu, H.; Rojas, M.; Xu, Z.; Lemtalsi, T.; Nagaoka, T.; Yoshida, A.; Brooks, S.E.; et al. Neuroprotection from retinal ischemia/reperfusion injury by NOX2 NADPH oxidase deletion. Investig. Ophthalmol. Vis. Sci. 2011, 52, 8123–8131. [Google Scholar] [CrossRef]
  121. Vorwerk, C.K.; Naskar, R.; Schuettauf, F.; Quinto, K.; Zurakowski, D.; Gochenauer, G.; Robinson, M.B.; Mackler, S.A.; Dreyer, E.B. Depression of retinal glutamate transporter function leads to elevated intravitreal glutamate levels and ganglion cell death. Investig. Ophthalmol. Vis. Sci. 2000, 41, 3615–3621. [Google Scholar]
  122. Rauen, T.; Rothstein, J.D.; Wässle, H. Differential expression of three glutamate transporter subtypes in the rat retina. Cell Tissue Res. 1996, 286, 325–333. [Google Scholar] [CrossRef] [PubMed]
  123. Brennan-Minnella, A.M.; Won, S.J.; Swanson, R.A. NADPH oxidase-2: Linking glucose, acidosis, and excitotoxicity in stroke. Antioxid. Redox Signal. 2015, 22, 161–174. [Google Scholar] [CrossRef] [PubMed]
  124. Wang, Z.; Wei, X.; Liu, K.; Zhang, X.; Yang, F.; Zhang, H.; He, Y.; Zhu, T.; Li, F.; Shi, W.; et al. NOX2 deficiency ameliorates cerebral injury through reduction of complexin II-mediated glutamate excitotoxicity in experimental stroke. Free Radic. Biol. Med. 2013, 65, 942–951. [Google Scholar] [CrossRef] [PubMed]
  125. Elksnis, A.; Cen, J.; Wikstrom, P.; Carlsson, P.O.; Welsh, N. Pharmacological inhibition of NOX4 improves mitochondrial function and survival in human beta-cells. Biomedicines 2021, 9, 1865. [Google Scholar] [CrossRef]
  126. Wang, X.; Elksnis, A.; Wikstrom, P.; Walum, E.; Welsh, N.; Carlsson, P.O. The novel NADPH oxidase 4 selective inhibitor GLX7013114 counteracts human islet cell death in vitro. PLoS ONE 2018, 13, e0204271. [Google Scholar] [CrossRef]
  127. Roufail, E.; Soulis, T.; Boel, E.; Cooper, M.E.; Rees, S. Depletion of nitric oxide synthase-containing neurons in the diabetic retina: Reversal by aminoguanidine. Diabetologia 1998, 41, 1419–1425. [Google Scholar] [CrossRef][Green Version]
  128. Barber, A.J. The form and Function of Retinal Ganglion Cells and Diabetes. Cells 2025, 14, 1455. [Google Scholar] [CrossRef]
  129. Potilinski, M.C.; Lorenc, V.; Perisset, S.; Gallo, J.E. Mechanisms behind Retinal Ganglion Cell Loss in Diabetes and Therapeutic Approach. Int. J. Mol. Sci. 2020, 21, 2351. [Google Scholar] [CrossRef]
  130. Yi, J.; Puyang, Z.; Feng, L.; Duan, L.; Liang, P.; Backman, V.; Liu, X.; Zhang, H.F. Optical detection of early damage in retinal ganglion cells in a mouse model of partial optic nerve crush injury. Investig. Ophthalmol. Vis. Sci. 2016, 57, 5665–5671. [Google Scholar] [CrossRef][Green Version]
  131. Soto, I.; Oglesby, E.; Buckingham, B.P.; Son, J.L.; Roberson, E.D.; Steele, M.R.; Inman, D.M.; Vetter, M.L.; Horner, P.J.; Marsh Armstrong, N. Retinal ganglion cells downregulate gene expression and lose their axons within the optic nerve head in a mouse glaucoma model. J. Neurosci. 2008, 28, 548–561. [Google Scholar] [CrossRef][Green Version]
  132. Peng, P.H.; Lin, H.S.; Lin, S. Nerve fibre layer thinning in patients with preclinical retinopathy. Can. J. Ophthalmol. 2009, 44, 417–422. [Google Scholar] [CrossRef]
  133. Vujosevic, S.; Midena, E. Retinal layers changes in human preclinical and early clinical diabetic retinopathy support early retinal neuronal and Müller cells alterations. J. Diabetes Res. 2013, 2013, 905058. [Google Scholar] [CrossRef] [PubMed]
  134. Rossino, M.G.; Lulli, M.; Amato, R.; Cammalleri, M.; Dal Monte, M.; Casini, G. Oxidative stress induces a VEGF autocrine loop in the retina: Relevance for diabetic retinopathy. Cells 2020, 9, 1452. [Google Scholar] [CrossRef] [PubMed]
  135. Grigsby, J.G.; Allen, D.M.; Ferrigno, A.S.; Vellanki, S.; Pouw, C.E.; Hejny, W.A.; Tsin, A.T.C. Autocrine and paracrine secretion of vascular endothelial growth factor in the pre-hypoxic diabetic retina. Curr. Diabetes Rev. 2017, 13, 161–174. [Google Scholar] [CrossRef]
  136. Saint-Geniez, M.; Maharaj, A.S.; Walshe, T.E.; Tucker, B.A.; Sekiyama, E.; Kurihara, T.; Darland, D.C.; Young, M.J.; D’Amore, P.A. Endogenous VEGF is required for visual function: Evidence for a survival role on Müller cells and photoreceptors. PLoS ONE 2008, 3, e3554. [Google Scholar] [CrossRef] [PubMed]
  137. Bucolo, C.; Ward, K.W.; Mazzon, E.; Cuzzocrea, S.; Drago, F. Protective effects of a coumarin derivative in diabetic rats. Investig. Ophthalmol. Vis. Sci. 2009, 50, 3846–3852. [Google Scholar] [CrossRef]
  138. Schrufer, T.L.; Antonetti, D.A.; Sonenberg, N.; Kimball, S.R.; Gardner, T.W.; Jefferson, L.S. Ablation of 4E-BP1/2 prevents hyperglycemia-mediated induction of VEGF expression in the rodent retina and in Müller cells in culture. Diabetes 2010, 59, 2107–2116. [Google Scholar] [CrossRef]
  139. Qaum, T.; Xu, Q.; Joussen, A.M.; Clemens, M.W.; Qin, W.; Miyamoto, K.; Hassessian, H.; Wiegand, S.J.; Rudge, J.; Yancopoulos, G.D.; et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Investig. Ophthalmol. Vis. Sci. 2001, 42, 2408–2413. [Google Scholar]
  140. Krady, J.K.; Basu, A.; Allen, C.M.; Xu, Y.; LaNoue, K.F.; Gardner, T.W.; Levison, S.W. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 2005, 54, 1559–1565. [Google Scholar] [CrossRef]
  141. Zeng, X.X.; Ng, Y.K.; Ling, E.A. Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis. Neurosci. 2000, 17, 463–471. [Google Scholar] [CrossRef]
  142. Rungger-Brändle, E.; Dosso, A.A.; Leuenberger, P.M. Glial reactivity, an early feature of diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2000, 41, 1971–1980. [Google Scholar]
  143. Grigsby, J.G.; Cardona, S.M.; Pouw, C.E.; Muniz, A.; Mendiola, A.S.; Tsin, A.T.C.; Allen, D.M.; Cardona, A.E. The role of microglia in diabetic retinopathy. J. Ophthalmol. 2014, 2014, 705783. [Google Scholar] [CrossRef]
  144. Ciudin, A.; Espinosa, A.; Ruiz, A.; Alegret, M.; Hernandez, C.; Boada, M.; Simó, R. Type 2 diabetes is an independent risk factor for dementia conversion in patients with mild cognitive impairment. J. Diabetes Its Complicat. 2017, 31, 1272–1274. [Google Scholar] [CrossRef]
  145. Little, K.; Llorian-Salvador, M.; Scullion, S.; Hernandez, C.; Simo-Servat, O.; Del Marco, A.; Bosma, E.; Vargas-Soria, M.; Caranza-Naval, M.; Van Bergen, T.; et al. Common Pathways in dementia and diabetic retinopathy: Understanding the mechanisms of diabetes related cognitive decline. Trends Endocrinol. Metab. 2022, 33, 50–71. [Google Scholar] [CrossRef]
  146. Pedersen, F.N.; Stokholm, F.; Pouwer, K.; Hass, R.; Peto, T.; Frydkjær-Olsen, U.; Suhr, A.; Thykjær, N.; Andersen, N.; Andersen, N.; et al. Diabetic Retinopathy Predicts Risk of Alzheimer’s Disease: A Danish Registry-Based Nationwide Cohort Study. J. Alzheimer’s Dis. 2022, 86, 451–460. [Google Scholar] [CrossRef]
  147. Pearce, I.; Simo, R.; Lovestan-Adrian, M.; Wong, D.T. Association between diabetic eye disease and other complications. A systematic review. Diabetes Obes. Metab. 2019, 21, 467–478. [Google Scholar] [CrossRef]
  148. Wang, D.; Li, J.; Luo, G.; Zhou, J.; Wang, N.; Wang, S.; Zhao, R.; Cao, X.; Hao, L. Nox4 as a novel therapeutic target for diabetic vascular complications. Redox Biol. 2023, 64, 102781. [Google Scholar] [CrossRef]
Ijms 27 01879 g001
Figure 1. Mechanisms leading to Neurovascular Unit impairment in Diabetic Retinopathy.Chronic hyperglycemia, through the dysregulation of various metabolic pathways, can cause the manifestation of ischemic and excitotoxic conditions in retina, and the development of oxidative stress. These causative factors render the retinal tissue vulnerable to inflammatory insults, neurodegenerative and vascular changes, leading to the severe impairment of the retinal NVU and subsequently to the development of Diabetic Retinopathy [35,36,37].
Figure 1. Mechanisms leading to Neurovascular Unit impairment in Diabetic Retinopathy.Chronic hyperglycemia, through the dysregulation of various metabolic pathways, can cause the manifestation of ischemic and excitotoxic conditions in retina, and the development of oxidative stress. These causative factors render the retinal tissue vulnerable to inflammatory insults, neurodegenerative and vascular changes, leading to the severe impairment of the retinal NVU and subsequently to the development of Diabetic Retinopathy [35,36,37].
Ijms 27 01879 g001
Ijms 27 01879 g002
Figure 2. NADPH Oxidases (NOX) function and oxidative stress.NADPH oxidases’ sole role is the production of reactive oxygen species (ROS, O2−, H2O2). Different pathological stimuli, such as DR, cause an imbalance between ROS and antioxidant factors, due to increased production of ROS, from NOX and other endogenous ROS generating systems, leading to the development of oxidative stress. ROS; Reactive Oxygen Species, CNS; Central Nervous System [61].
Figure 2. NADPH Oxidases (NOX) function and oxidative stress.NADPH oxidases’ sole role is the production of reactive oxygen species (ROS, O2−, H2O2). Different pathological stimuli, such as DR, cause an imbalance between ROS and antioxidant factors, due to increased production of ROS, from NOX and other endogenous ROS generating systems, leading to the development of oxidative stress. ROS; Reactive Oxygen Species, CNS; Central Nervous System [61].
Ijms 27 01879 g002
Ijms 27 01879 g003
Figure 3. Schematic model of NADPH oxidase actions in ESDR.Diabetes-induced increase in NOX2 and NOX4 activation leads to the accumulation of ROS. This in turn initiates apoptosis, of neuronal and vascular cells, glial activation, and enhances inflammation (e.g., via NF-κB signaling pathway, VEGF expression). At a subsequent level, NOX-derived ROS produced by activated glial cells further deteriorates NVU by increasing neuroinflammation, vasculopathy and neurodegeneration. NADPH oxidase inhibition represents a promising therapeutic approach for the early-stage DR, thus ameliorating the progression of the disease.
Figure 3. Schematic model of NADPH oxidase actions in ESDR.Diabetes-induced increase in NOX2 and NOX4 activation leads to the accumulation of ROS. This in turn initiates apoptosis, of neuronal and vascular cells, glial activation, and enhances inflammation (e.g., via NF-κB signaling pathway, VEGF expression). At a subsequent level, NOX-derived ROS produced by activated glial cells further deteriorates NVU by increasing neuroinflammation, vasculopathy and neurodegeneration. NADPH oxidase inhibition represents a promising therapeutic approach for the early-stage DR, thus ameliorating the progression of the disease.
Ijms 27 01879 g003
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Dionysopoulou, S.; Thermos, K. Role of NADPH Oxidases as Novel Therapeutic Targets for the Impaired Neurovascular Unit in the Early Stage of Diabetic Retinopathy. Int. J. Mol. Sci. 2026, 27, 1879. https://doi.org/10.3390/ijms27041879

AMA Style

Dionysopoulou S, Thermos K. Role of NADPH Oxidases as Novel Therapeutic Targets for the Impaired Neurovascular Unit in the Early Stage of Diabetic Retinopathy. International Journal of Molecular Sciences. 2026; 27(4):1879. https://doi.org/10.3390/ijms27041879

Chicago/Turabian Style

Dionysopoulou, Stavroula, and Kyriaki Thermos. 2026. "Role of NADPH Oxidases as Novel Therapeutic Targets for the Impaired Neurovascular Unit in the Early Stage of Diabetic Retinopathy" International Journal of Molecular Sciences 27, no. 4: 1879. https://doi.org/10.3390/ijms27041879

APA Style

Dionysopoulou, S., & Thermos, K. (2026). Role of NADPH Oxidases as Novel Therapeutic Targets for the Impaired Neurovascular Unit in the Early Stage of Diabetic Retinopathy. International Journal of Molecular Sciences, 27(4), 1879. https://doi.org/10.3390/ijms27041879

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop